Current Problems in Cancer RSS feed: Current Issue. Each bimonthly issue of Current Problems in Cancer presents a single-topic, in-depth discussion, usually focused on the integrated management of a particular type of cancer or on a problem faced in a wide variety of malignancies. Issues may explore a particular category of drugs, an emerging interventional technique, or rehabilitation/reconstruction. Extensive bibliographies allow readers to easily locate additional information on related topics. Current Problems in Cancer serves the wide spectrum of physicians who treat patients with neoplastic disease. 2008 Topics , Volume 32, Issues 1-6 January ARhabdomyosarcoman A. Paulino March Biomarkers and Cancer Stem Cells in Primary Brain Tumors R. Sawaya, & O. Bogler May Cutaneous Lymphoma L. Wilson, & B. Smith July Currative Therapy for Radiorecurrent Prostate Cancer J. Ward September Immune Reconstitution in Graft Versus Lukemia Therapy M. Verneris November Gastric Cancer H. Lenz, & A. El-Khoueiryhttp://www.cpcancer.com/?rss=yesElsevier Inc.en © 2009 Published by Elsevier Inc. All rights reserved. Current Problems in Cancer0147-0272335September 2009 © 2009 Published by Elsevier Inc. All rights reserved. healthpermissions@elsevier.comhttp://www.cpcancer.com/article/PIIS0147027209000610/abstract?rss=yesTitle Page10.1016/S0147-0272(09)00061-0Current Problems in Cancer 33, 5 (2009)2009-09-01Current Problems in Cancer2009-09-01335S0147-0272(09)X0005-X295295http://www.cpcancer.com/article/PIIS0147027209000622/abstract?rss=yesInformation for Readers10.1016/S0147-0272(09)00062-2Current Problems in Cancer 33, 5 (2009)2009-09-01Current Problems in Cancer2009-09-01335S0147-0272(09)X0005-X296296http://www.cpcancer.com/article/PIIS0147027209000634/abstract?rss=yesTable of Contents10.1016/S0147-0272(09)00063-4Current Problems in Cancer 33, 5 (2009)2009-09-01Current Problems in Cancer2009-09-01335S0147-0272(09)X0005-X297298http://www.cpcancer.com/article/PIIS0147027209000646/abstract?rss=yesAuthor Bio Sketch10.1016/S0147-0272(09)00064-6Current Problems in Cancer 33, 5 (2009)2009-09-01Current Problems in Cancer2009-09-01335S0147-0272(09)X0005-X299300http://www.cpcancer.com/article/PIIS014702720900049X/abstract?rss=yesThe history of anal cancer therapy provides the first evidence that judicious application of chemoradiation could obviate the need for surgery; with that discovery, the concept of organ-sparing therapy was born. Since then, the construct has been expanded most successfully to laryngeal preservation but also to other specific sites (eg, orbit, extremity) for some pediatric malignancies. Yet, in the study of anal cancer, we still have much ahead of us. Sphincter-sparing rates are not 100%, and loss of sphincter function is not uncommon. Cutaneous toxicity is marked.ForewordPeter A.S. Johnstone10.1016/j.currproblcancer.2009.10.004Current Problems in Cancer 33, 5 (2009)2009-09-01Current Problems in Cancer2009-09-01335S0147-0272(09)X0005-X301301http://www.cpcancer.com/article/PIIS0147027209000488/abstract?rss=yesIt is estimated that there will be 5290 new cases of anal cancer diagnosed in the USA this year and 710 deaths from anal cancer this year. It makes up less than 2% of all gastrointestinal (GI) malignancies. It afflicts women more than men, except in people younger than age 35, where the prevalence is higher in men than women. Most anal cancers are epidermoid tumors, with histologic types ranging from squamous cell carcinoma to cloacogenic or basaloid. Regardless of histology, all anal epidermoid tumors are treated similarly. Other tumor types that occur more rarely in the anal canal include adenocarcinoma, lymphoma, melanoma, and Merkel cell tumor, and treatment for these tumor types is tailored for the specific tumor type. This review will focus on the management of epidermoid anal cancer.Anal Cancer: Progress on Combined-Modality and Organ PreservationEmily Chan, Lisa A. Kachnic, Charles R. Thomas10.1016/j.currproblcancer.2009.10.003Current Problems in Cancer 33, 5 (2009)2009-09-01Current Problems in Cancer2009-09-01335S0147-0272(09)X0005-X302326